In the present study, the preparation, characterization and activity of non-phospholipid vesicles (NPV) containing three aminoacid-based molecules were described. As model compounds trypsin, bovine basic pancreatic inhibitor and polylysine rich peptides derived from the herpes simplex virus type 1 (HSV-1) glycoprotein B were employed. NPV were chosen as alternative to liposomes for the possible administration of aminoacid based molecules via mucous membrane (nasal or vaginal) routes. NPV containing the indicated model drugs have shown to be more stable in term of size with respect to liposomes encapsulating the same model drugs previously produced by our group [Cortesi, R. Argnani, R., Esposito, E., Dalpiaz, A. Scatturin, A., Bortolotti, F., Lufino, M., Guerrini, R., Incorvaia, C., Menegatti, E., Manservigi, R., 2006. Cationic liposomes as potential carriers for ocular administration of peptides with antiherpetic activity. Int. J. Pharm. 317, 90–100]. In addition our study indicates that the produced NPV (i) are able to encapsulate the model drugs over 49%, (ii) are characterized by dimensions compatible with applications on the mucous membrane, (iii) remain stable in size for at least 3 months and (iv) can release the model drug (after a slight lag time) in a controlled fashion as compared to that of the corresponding free solution.
Non-phospholipid vesicles as carriers for peptides and proteins: production, characterization and stability studies / Cortesi, R.; Esposito, E.; Corradini, F.; Sivieri, E.; Drechsler, M.; Rossi, Alessandra; Scatturin, A.; Menegatti, E.. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - 339 (1-2):(2007), pp. 52-60. [10.1016/j.ijpharm.2007.02.024]
Non-phospholipid vesicles as carriers for peptides and proteins: production, characterization and stability studies
ROSSI, Alessandra;
2007-01-01
Abstract
In the present study, the preparation, characterization and activity of non-phospholipid vesicles (NPV) containing three aminoacid-based molecules were described. As model compounds trypsin, bovine basic pancreatic inhibitor and polylysine rich peptides derived from the herpes simplex virus type 1 (HSV-1) glycoprotein B were employed. NPV were chosen as alternative to liposomes for the possible administration of aminoacid based molecules via mucous membrane (nasal or vaginal) routes. NPV containing the indicated model drugs have shown to be more stable in term of size with respect to liposomes encapsulating the same model drugs previously produced by our group [Cortesi, R. Argnani, R., Esposito, E., Dalpiaz, A. Scatturin, A., Bortolotti, F., Lufino, M., Guerrini, R., Incorvaia, C., Menegatti, E., Manservigi, R., 2006. Cationic liposomes as potential carriers for ocular administration of peptides with antiherpetic activity. Int. J. Pharm. 317, 90–100]. In addition our study indicates that the produced NPV (i) are able to encapsulate the model drugs over 49%, (ii) are characterized by dimensions compatible with applications on the mucous membrane, (iii) remain stable in size for at least 3 months and (iv) can release the model drug (after a slight lag time) in a controlled fashion as compared to that of the corresponding free solution.File | Dimensione | Formato | |
---|---|---|---|
non phospholipid vesicles.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
984.04 kB
Formato
Adobe PDF
|
984.04 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
abstract_non phospholipid vesicles.docx
non disponibili
Tipologia:
Abstract
Licenza:
Creative commons
Dimensione
83.79 kB
Formato
Microsoft Word XML
|
83.79 kB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.